Anne Li May 6th, 2017
A blood test could help predict which advanced prostate cancer patients are likely to do best when treated with certain targeted treatments. The test, developed by scientists at The Institute of Cancer Research (ICR) and Royal Marsden NHS Foundation Trust, detects DNA released by cancer cells into the bloodstream. Men whose blood samples carried multiple copies of a particular gene tended to do worse when treated with the drugs abiraterone (Zytiga) and enzalutamide (Xtandi) – the standard treatment for advanced prostate cancer.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-05-04-experimental-blood-test-predicts-advanced-prostate-cancer-outcome